THERAPEUTIC VACCINES TO REDUCE OCULAR HSV RECURRENCE

描述（改编自申请人摘要）： 这一建议建议旨在减少疱疹诱发的发病率 通过治疗性疫苗接种致盲。在以往的研究中 在此期间，研究者已表明治疗性疫苗在 减少HSV-1眼部复发的统计学显著性术语 疾病和HSV-1脱落。研究人员假设， 观察到的治疗性疫苗效力是由于局部眼/粘膜免疫 而不是全身免疫反应。研究者 工作组编写了四份文件， 治疗性疫苗所有论文都已提交 (none接受）。目前要解决的具体目标 应用是（1）测试治疗性疫苗 可以通过以下方法延长对复发性眼部HSV-1的效力和持续时间 眼周加强接种亚单位疫苗或HSV-1 DNA眼用疫苗或HSV-1眼用活疫苗;（2）检测 复发性眼病治疗性疫苗有效性假说 HSV-1是由于常见的粘膜免疫，而不仅仅是局部眼 粘膜免疫;（3）验证sIgA是粘膜免疫的假设。 对治疗性疫苗最重要特异性粘膜免疫应答 对复发性眼部HSV-1的疗效。

DESCRIPTION (Adapted from the applicant's abstract): This proposal proposes to reduce the incidence of herpes induced blindness through therapeutic vaccination. In the previous research period, the investigator has indicated therapeutic vaccine efficacy in terms of statistically significant that reduced recurrent HSV-1 ocular disease and HSV-1 shedding. The investigator has hypothesized that the therapeutic vaccine efficacy seen is due to local ocular/mucosal immune response rather than a systemic immune response. The investigator's group has produced four papers directly related to their work on therapeutic vaccination. All papers have been submitted at this time (none accepted). The specific aims to be addressed in the present application are (1) to test the hypothesis that therapeutic vaccine efficacy and duration against recurrent ocular HSV-1 can be extended by periocular booster inoculations with a subunit vaccine, or with HSV-1 DNA ocular vaccines or live HSV-1 ocular vaccines; (2) to test the hypothesis that therapeutic vaccine efficacy against recurrent ocular HSV-1 is due to common mucosal immunity rather than just local ocular mucosal immunity; and (3) to verify the hypothesis that sIgA is the specific mucosal immune response most important for therapeutic vaccine efficacy against recurrent ocular HSV-1.